High-Risk Cervical Human Papillomavirus Infections among Human Immunodeficiency Virus-Positive Women in the Bahamas

Dionne N. Dames1, Elizabeth Blackman2*, Raleigh Butler3, Emanuela Taioli4, Stacy Eckstein5, Karthik Devarajan6, Andrea Griffith-Bowe3, Perry Gomez1, Camille Ragin2*, on behalf of the African Caribbean Cancer Consortium1

1 Department of Medicine, Princess Margaret Hospital, Nassau, Bahamas, 2 Cancer Prevention and Control Program, Fox Chase Cancer Center – Temple University Health System, Philadelphia, PA, USA, 3 Department of Obstetrics & Gynecology, Princess Margaret Hospital, Nassau, Bahamas, 4 Department of Population Health, North Shore Long Island Jewish/Hofstra School of Medicine, Manhasset, NY, USA, 5 Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 6 Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA

Abstract

Background: High-risk (HR) HPV genotypes other than 16 and 18 have been detected in a significant proportion of immunocompromised females. We aim to evaluate the frequency of HR HPV genotypes in a population of HIV-positive Caribbean women.

Methods: One hundred sixty-seven consecutive, non-pregnant, HIV-positive females ≥18 years were recruited in this study. Each participant received a vaginal examination, PAP smear, and completed a questionnaire. DNA was extracted for HPV testing in 86 patients.

Results: Mean age was 39.1 years for women positive for HR HPV and 43.1 years for women negative for HR HPV (P value = 0.040). 78% (130/167) of the women had HR HPV infections; the prevalence of abnormal cervical cytology was 38% among women who were HR HPV-positive compared to women who were HR HPV-negative (22%). Fifty-one percent of the 86 women with available genotype carried infections with HPV 16 and/or HPV 18; genotypes of unknown risk were also frequently observed. Women who had a CD4+ count of ≤200 had 7 times increased odds of carrying HR HPV infection in comparison to women with CD4+≥200.

Conclusions: HR HPV infections in HIV infected females may consist of more than just HPV 16 and 18, but also HPV 52 and 58. Further studies are needed to determine whether HPV 52 and 58 play a significant role in the development of cervical cytological abnormalities in HIV+ women.

Introduction

Human Immunodeficiency Virus (HIV) infection leads to a decline in both the number and function of CD4+ T cells. This deficiency in the immune system places the infected person at risk for other infections. For example, Human papillomavirus (HPV) is the most common sexually transmitted virus that infects the cervix and is the major etiologic agent for cervical cancer. Studies show that immunodeficiency increases HPV persistence thus increasing the risk of cervical cytology abnormalities and invasive cervical cancer [1,2].

High-risk (HR) HPV types 16 and 18 account for the majority of all invasive cervical cancers worldwide (56.6% and 16%, respectively), while HPV 58, 33, 45, 31, 52, 35, 59, 39, 51 and 56 in order of decreasing prevalence account for the other 27.4% of all invasive cancers worldwide [3]. Similarly in the Caribbean, 56.8% of all invasive cervical cancers are attributed to HPV 16, and 6.7% to HPV 18; HPV 31, 45, 39, 51, 52, 56, 59 and 73 in order of decreasing prevalence account for the other 35.5% of cancers [4]. In 2006, a meta-analysis of HPV infections in HIV-positive women (n = 5,578) suggested that HPV 16 is less prevalent among HIV positive women with high-grade cervical lesions, and
that other subtypes (11, 18, 33, 51, 52, 53, 58 and 61) are also substantially represented in this population [5]. At the time of the meta-analysis, however, no studies had been conducted in the Caribbean islands. In 2009, we conducted a study of cervical HPV infection in HIV-positive Caribbean women living in the Bahamas and observed that 46% of women with normal cervical cytology were infected with HR HPV, and that the prevalence was 100% for women with high-grade cervical lesions [6]. HPV genotyping was not evaluated in this study; therefore the type-specific prevalence and distribution of the various HPV types in HIV-positive women in the Caribbean population was still unknown.

HPV-positive persons treated with highly active anti-retroviral therapy (HAART) have reconstitution of the immune system following a successful lowering of HIV viral load and an increase in CD4+ T cell counts. These patients are no longer dying predominantly from opportunistic infections, but may be affected by other chronic medical illnesses and malignancies. A recent review by Adler et al [7] suggests that HAART has limited ability in decreasing HPV-associated cervical cancers in HIV-positive women. There are no studies addressing this issue conducted for HIV-positive women in the Caribbean.

In this study, the objectives are to evaluate the frequency and distribution of HR HPV genotypes in a population of HIV-positive Caribbean women and determine whether HR HPV infections other than HPV 16 and 18 are predominant in women with abnormal cervical cytology.

## Methods

### Study Population

The study received ethical approval from the Ethics Committee of the Public Hospital Authority and the University of the West Indies – Bahamas Campus. All participants provided written informed consent. Following Institutional Review Board approvals, 176 consecutive non-pregnant, HIV sero-positive females 18 years or older were recruited from the Infectious Disease Clinic at the Princess Margaret Hospital (PMH) in New Providence, Nassau, Bahamas from February to September, 2008. Cervical samples were collected through a PAP smear from all women at the time of the visit, and DNA was extracted for HPV testing. Nine women were excluded from the study due to insufficient quality DNA; therefore, the final study population consisted of 167 women. The first 80 patients were part of a previous publication [6]. All women had a positive HIV status via ELISA and Western blot methods; none of the women reported having used IV drugs in their life-time.

The Infectious Disease Clinic at PMH caters to all the Bahaman Islands where the majority of persons (70%) reside in New Providence, Nassau and each year about 1,500 HIV-positive women are seen. This clinic’s mandate is to cater to and treat all patients regardless of immigration status, nationality or finances by providing access to antiretrovirals and care. As a result, a small percentage of patients from other Caribbean countries are also seen at the clinic. Our study population reflects this demographic, whereby 93% (n = 155) of women are from Bahamas, while 7% are from other Caribbean countries (such as Haiti (5%, n = 9) and Jamaica (2%, n = 3)).

### Data collection

Each participant received a vaginal examination, Pap Smear and completed a questionnaire administered by an interviewer. The questionnaire collected demographic information, tobacco and alcohol use, reproductive information such as number of pregnancies, age at first menses, number of sexual partners, age at first intercourse, history of sexually transmitted infections.

Clinical information was collected for each participant and included the number of years diagnosed with HIV, number of years on HAART and compliance with therapy. In the Infectious Disease clinic, patients were initiated on HAART when their CD4 count was less than 350 cells/µL. For all women, results from HIV testing (ELISA and Western Blot), CD4 counts (Flow Cytometry), HIV viral load (Polymerase Chain Reaction (PCR)) and HR HPV status (Hybrid Capture II (HC II)) were recorded in the patient records in a clinical data base. The HPV testing, viral load and CD4 counts were performed in the clinical laboratory at the Princess Margaret Hospital. The HC II assay was performed in a clinical laboratory at LabCorp in the USA (Miami, Florida). Review of patient records was performed to obtain these results for inclusion in this study. The participant’s last CD4 count and HIV viral load were recorded. These tests were performed either at the time the cervical sample was obtained or within the previous two months.

### HPV testing

The HC II assay is capable of identifying HR HPV infections (HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), results are reported as “detected” or “not detected” and were available from the medical records for 81 patients in this study. For the remaining 86 patients, cervical thin-prep samples were shipped to the United States (Ragin laboratory) where HPV genotyping was performed using the HPV Linear Array protocol. To confirm that the extracted DNA samples were PCR amplifiable, the β-globin gene fragment was amplified using PCO4 and GH20 PCR primers. All DNA extraction and PCR set-up were performed in a PCR-clean area separate from the post-DNA amplification areas in the laboratory. The specific HPV types in each cervical specimen were identified using a Linear Array HPV genotyping protocol as previously described [8]. Briefly, the linear array assay included a PCR-based protocol involving biotin-labeled primers which detected the 37 most common HPV genotypes identified in cervical mucosa. The PCR products were denatured and hybridized to strips containing HPV-specific oligonucleotide probes. A colorimetric change indicated the presence of a given HPV type. The HPV types identified by the Linear Array method includes [Low-risk: 6, 11, 40, 42, 54, 61, 70, 72, 81, 64, 108; High Risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82; Probable High Risk: 26, 53, 66; and Unknown Risk: 55, 62, 64, 67, 69, 71, 83, 84, IS39].

Both the Linear Array and HC II assays are comparable for HR HPV status since each detects the same HR HPV genotypes which are classified based on the previously published risk classification by Munoz et al. [9]. Therefore the results from both assays were combined for HR HPV analyses. The Linear Array additionally detects HPV 73 and 82 which are also classified as “high-risk”. Patient samples that were HCII-positive had at least one HR HPV type detected by the Linear Array were categorized as HR HPV-positive. Patient samples with “probably high-risk” HPV genotypes were often co-infected with one or more other HR HPV genotypes (14/16, 88%) therefore were also categorized as HR HPV-positive. Since low-risk HPV types are not etiologically linked to cervical carcinogenesis [10] and there is no clinical benefit for evaluating low-risk HPV status for cervical cancer risk, study participants who were HPV-negative and/or infected with low-risk HPV types, and/or infected with undetermined risk were categorized as HR HPV-negative. Women with HR HPV findings were counseled and referred for usual clinical care; similarly,
women with cervical lesions were referred to further testing and treatment.

**Statistical Analysis**

Age was categorized into tertiles (19–35 years, 36–45 years, and 46+ years). Age at first intercourse was categorized as a binary variable based on mean age of responses to the question (≤16 years and >16 years). Current contraceptive use was categorized as yes/no. Length of time on HAART was categorized as less than 2 years, 2–4 years, and greater than 4 years. CD4+ cell count and viral load were both divided into two groups based on the median value for each respective variable. Cervical cytology reports were categorized into three categories: negative, dysplasia (which includes low grade squamous intraepithelial lesion [LGSIL]) and high grade squamous intraepithelial lesion [HGSIL]), and atypical squamous cells of undetermined significance (ASCUS).

Descriptive statistics were generated for demographic, behavioral, and clinical variables according to the presence or absence of HR HPV infection, using Fisher’s exact test to determine statistically significant differences between the proportions for each variable. Multivariable logistic regression models were used to assess the association of demographic, behavioral, and clinical variables with HR HPV infections. Pair-wise association of each variable with HR HPV status was performed. Covariates were included in the models based on statistically significant associations with HR HPV status (p<0.05). For the subset of participants where specific HPV genotypes were available, multivariable logistic regression models were used to assess the association between demographic, behavioral, and clinical variables and the odds of having HR HPV types 16 or 18 versus any other HR HPV type. Statistical analysis was performed using STATA version 10.1 software (Stata LP, College Station, TX). A P value of ≤0.05 was considered statistically significant.

**Results**

**Descriptive Statistics of Overall Study Population**

The study population (n = 167) consisted of women, ages 19 to 71 years old (mean age: 40 years). Table 1 summarizes the demographic and behavioral characteristics of the women according to HR HPV status. The mean age of HR HPV-positive women was younger than that of HR HPV-negative women (39.1 years vs. 43.1 years; *P* value = 0.040). Overall 78% (130/167) of the women had HR HPV infections, and the prevalence of abnormal cervical cytology was 38% (49/130) among women who were HR HPV-positive compared to women who were HR HPV-negative (22% (8/37)). Cervical dysplasia rather than ASCUS was more prominent irrespective of HR HPV status. Seventy-seven percent (38/49) of HR HPV-positive women with abnormal cervical cytology had dysplasia compared to 62% (5/8) HR HPV-negative women with abnormal cervical cytology. As expected, a significantly higher proportion of women who carried HR HPV infections had HIV viral load ≥400 and CD4 count ≤200 compared to women who were HR HPV-negative. HR HPV-positive women were more likely to have had a history of pregnancy compared to HR HPV-negative women (*P* = 0.048). Among the women with available HPV genotype data (n = 86), a wide distribution of HR and low/unknown-risk HPV types was detected (Figure 1). The prevalence of HR HPV types range from 34.9% to 1.2%, and HPV 18 was the most frequently detected. HPV 16 and 18 were the most prevalent in younger women, (≤39 years) while HPV 18 and 58 were most prevalent in older women (>39 years) (data not shown). Similarly, the prevalence of Low-Risk HPV types (including genotypes of unknown risk) ranged from 26.7% to 1.25%; HPV 62, a genotype with unknown risk, was most frequently detected. Fifty-one percent of the 86 women with available genotype carried infections with HPV 16 and/or HPV 18. The majority, 73/86 (85%), carried multiple cervical HPV infections of any HPV type ranging from two to fifteen different HPVs in a single sample. With regard to HR HPV genotypes, women carried at least one or as many as 7 in any given sample.

**Multivariable Analysis**

Women who had a CD4+ count of ≤200 had 7 times increased odds of carrying HR HPV infection (Adjusted Odds Ratio [Adj OR] 7.27, 95% Confidence Interval [CI] 1.41–37.53-Table 2). There were no statistically significant associations between the other covariates and HR HPV infections (i.e. age, number of years on HAART, viral load and cervical cytology).

Among the 86 women for which specific HPV genotype data were available, 76 had HR HPV infections. For these women, after adjusting for possible confounders, women with a CD4 count ≤200 cell μL appeared more likely to be HPV 16/18 positive compared to women with a higher CD4 count, but this association was not statistically significant. No other variable was associated with carrying an HPV 16/18 infection in comparison to having another HR infection (Table 3).

**Discussion**

In this sample of HIV-positive Caribbean women, we report that HR types 16 and 18 were among the most commonly diagnosed HPVs, and that infections with HR HPV types 52 and 58 are frequent. Other studies involving HIV-positive women in the US and Africa have reported a high prevalence of HR HPV types other than HPV 16 and 18, and our study among Caribbean women is in line with these results. Sherestha et al noted an increased incidence and prevalence of HPV 58, 53/66, 68/70 and 31/33/35, in African American HIV-positive females [11]; these subtypes were more frequent than HPV 16 and 18. Similarly, Luque et al [12] determined that high-risk types other than 16 and 18 were the most prevalent in a diverse population of HIV-positive women in Rochester, New York. Types 56 and 53 occurred most frequently in that population, followed by HPV 16, 58, and 52. A Ugandan study with an HIV-positive female population conducted by Banura et al [13] revealed high-risk types 52, 33, 51, and 16 in this order. Finally, in Zambia, 145 HIV-positive women were evaluated and HPV 52, 50 and 53 was the most prevalent while HPV 16, 35 and 45 were less common in this study population [14].

The majority of women in our sample carried multiple HR HPV infections; this could be attributed, among others, to the immunosuppressive state due to HIV infection. Patel et al. reported that the risk of abnormal cervical cytology was increased among women who carried multiple HPV infections (OR = 6.0; 95% CI: 2.3–15.7) [15]; this may be partly attributed to a high prevalence of HPV infection, and to an increased likelihood of persistent infection due to HIV status [16,17,18,19]. Studies show that infections with multiple high-risk HPV types may act synergistically in cervical cancer development [20]. Therefore, the recommendation of routine cervical cancer screening in HIV-positive women is appropriate. At the time of this study cervical cancer screening, although available through the public clinics, was not routinely performed as part of the Infectious Diseases Clinic’s Programme. Since the completion of this study, the Gynecology department and HIV clinics at the Princess Margaret...
Hospital have revised their policies and now encourages HIV-positive women to have their Pap Smears at least annually.

Another interesting finding is that 78% of the women carried HR HPV subtypes, but only 38% presented with abnormal cervical cytology; this suggests that the majority of these infections were likely transient rather than persistent, or that these were new infections. In addition, a high rate of cervical abnormalities was observed among women without evidence of HR HPV types yet cervical dysplasia rather than ASCUS was more frequently diagnosed. Assuming that HPV remains the main risk factor for cervical cancer in the Caribbean, this finding may indicate that other HPV types, considered low risk, are actually responsible, alone or in combination with specific environmental/behavioral factors, for the observed cervical abnormalities.

There is limited epidemiologic evidence of a specific role of HPV 52 and 58 in cancer development in HIV-positive women. Although high-risk HPV types 16 and 18 are known to be associated with more than 70% of all cervical cancer cases, few studies suggest that this may not necessarily hold true for immunocompromised populations of non-European descent. Sahasrabuddhe et al. screened over 145 HIV-positive Zambian women and detected squamous cell carcinoma in 28 females. Thirteen (46.4%) SCC cases were positive for HPV 52, and 10 (35.7%) cases were positive for both HPV 58 and 16 [14].

### Table 1. Summary of demographic and behavioral characteristics of Bahamas HIV-positive women according to their HR HPV status.

| Characteristic                      | HPV HR Positive (%) | HPV HR Negative (%) | P value* |
|------------------------------------|---------------------|---------------------|----------|
|                                    | N = 130             | N = 37              |          |
| **Age (years)**                    |                     |                     |          |
| 19–35                              | 51 (39.2)           | 7 (18.9)            | 0.065    |
| 36–45                              | 43 (33.1)           | 16 (43.2)           |          |
| 46+                                | 36 (27.7)           | 14 (37.8)           |          |
| **Age at 1st intercourse (years)** |                     |                     | 0.853    |
| ≤16                                | 70 (53.9)           | 19 (51.3)           |          |
| >16                                | 60 (46.1)           | 18 (48.7)           |          |
| **Current contraceptive use**      |                     |                     | 0.563    |
| No                                 | 73 (58.4)           | 18 (51.4)           |          |
| Yes                                | 52 (41.6)           | 17 (48.6)           |          |
| **Number of Pregnancies**          |                     |                     | 0.048    |
| 0                                  | 9 (6.9)             | 0                   |          |
| 1–3                                | 63 (48.5)           | 13 (35.1)           |          |
| >3                                 | 58 (44.6)           | 24 (64.9)           |          |
| **Presently on HAART**             |                     |                     | 1.000    |
| Yes                                | 105 (81.4)          | 29 (80.6)           |          |
| No                                 | 24 (18.6)           | 7 (19.4)            |          |
| **Number of Years on HAART**       |                     |                     | 0.063    |
| <2 years                           | 33 (31.4)           | 6 (20.7)            |          |
| 2–4 years                          | 43 (41.0)           | 8 (27.6)            |          |
| >4 years                           | 29 (27.6)           | 15 (51.7)           |          |
| **Number of Years known HIV-positive** |                   |                     | 0.579    |
| <3                                 | 51 (39.2)           | 11 (29.7)           |          |
| >3                                 | 47 (36.2)           | 15 (40.5)           |          |
| >9 years                           | 32 (24.6)           | 11 (29.7)           |          |
| **Last Viral Load mL**             |                     |                     | 0.001    |
| <400                               | 56 (43.1)           | 27 (73.0)           |          |
| ≥400                               | 74 (56.9)           | 10 (27.0)           |          |
| **Last CD4 Count cell/µL**         |                     |                     | <.0001   |
| ≤200                               | 55 (42.3)           | 3 (8.1)             |          |
| >200                               | 75 (57.7)           | 34 (91.9)           |          |
| **Cervical Cytology**              |                     |                     | 0.079    |
| Normal                             | 81 (62.3)           | 29 (78.4)           |          |
| Abnormal*                          | 49 (37.7)           | 8 (21.6)            |          |

*Fisher’s exact test p-values; † Data missing for 7 women; Yes: birth control and male condoms, No: abstinence, sterilization and no method of birth control used; ¥ Data missing for 2 women; ‡ Includes women who answered “yes” to being on treatment but also answered “0” to number of years on treatment; ¥ Includes ASCUS, Reactive and dysplasia.

doi:10.1371/journal.pone.0085429.t001
Similarly, Maranga et al. reported a lower prevalence of HPV 16 and 18 in HIV-positive women with invasive cervical carcinoma compared to HIV-negative women with invasive cervical carcinoma [21]. In the present study, none of the study participants had invasive cervical carcinoma; therefore, associations between HPV52 and 58 with SCC cannot be explored in this sample. However, the next step will be to follow prospectively these women to determine whether these HR HPV types are associated with cancer development. This has public health relevance since the current vaccines only target types 16 and 18, thus offering little protection if other HR HPV types are shown to play a role in the immunocompromised population.

Our study has several limitations: despite the fact that we enrolled all consecutive patients from the Clinic, we cannot exclude that some selection bias occurred, thus we cannot affirm that the results have external validity for the entire HIV positive community in the Bahamas. In addition, only a subset of the study population had available type-specific HPV information. Another limitation in this study is that, given the retrospective nature of the design, the participant’s last CD4 count and HIV viral load were either performed at the time of enrollment or within the previous

Table 2. Association between clinical factors and HR HPV infection (n = 167).

| Variable                  | Adjusted Odds Ratio* | 95% Confidence Interval |
|---------------------------|----------------------|-------------------------|
| Number of Years on HAART  |                      |                         |
| <2 years                  | 1.0                  | ref                     |
| 2–4 years                 | 1.54                 | (0.43–5.56)             |
| >4 years                  | 0.55                 | (0.17–1.82)             |
| Last CD4 count cell/μL    |                      |                         |
| >200                      | 1.0                  | ref                     |
| ≤200                      | 7.27                 | (1.41–37.53)            |
| Last Viral Load mL⁻¹      |                      |                         |
| <400                      | 1.0                  | ref                     |
| ≥400                      | 1.62                 | (0.47–5.51)             |
| Cervical Cytology         |                      |                         |
| Negative                  | 1.0                  | ref                     |
| ASCUS & Reactive          | 0.74                 | (0.16–3.44)             |
| Dysplasia (HGSIL or LGSIL)| 1.75                 | (0.42–7.32)             |

*Adjusted for age, length of time on HAART, CD4+ count, viral load, and cervical abnormalities.

doi:10.1371/journal.pone.0085429.t002
two months. In the first month after initiating HAART, CD4 count will start to rise, and will continue to rise for the first three years on average before reaching a plateau. It is possible that the levels of CD4 and viral load may be inaccurate in patients where CD4 count will start to rise, and will continue to rise for the first three months. In the first month after initiating HAART, CD4 exfoliated compared to biopsy specimens. Another limitation of this study is that we examined exfoliated cervical cells rather than cervical biopsies. A recent study compared HPV prevalence and genotype infections between exfoliated cells and the corresponding cervical biopsy from women who HIV-positive [22]. Among women diagnosed with CIN2/3, the prevalence of HPV and multiple HPV types were similar in the biopsy compared to the exfoliated cells. This was in contrast to HIV-positive women with normal cervical cytology where the prevalence of HPV and multiple HPV types was higher in exfoliated cells compared to biopsy specimens. Another limitation is that the retrospective nature of the study does not allow us to assess a causal relationship between the length of time on HAART and the risk of developing abnormal cervical cytology.

Our findings support the need for follow-up of HIV-positive women in a longitudinal study in the Bahamas. The data generated from these efforts would provide important clinical information related to HPV persistence and the dynamics of multiple infections with HR HPV types in this population. Comparisons of HPV infections between cervical biopsies and exfoliated cells would provide meaningful information for the development of appropriate screening and HPV triage protocols needed for the evaluation and management of HPV infections in HIV-positive women.

Conclusions

To our knowledge our work represents the first study of HR HPV infections in a unique population of Black HIV-positive women treated in the Bahamas. Our findings correlate with what has been reported in other populations. This information will need to be confirmed in larger studies but already warrants the significance of HPV screening in HIV-positive populations. Furthermore, the findings from our study could provide some insight on the potential efficacy of the current HPV vaccines in a population where HIV infection is wide-spread.

Acknowledgments

The authors would like to thank Dr. Carolyn Fang, Fox Chase Cancer Center for her critical review of the manuscript as well as the anonymous reviewers who provided constructive comments on this manuscript. The African Caribbean Cancer Consortium comprises: Butler R, Griffith-Bowe A, Dames DN (Princess Margaret Hospital, Nassau, Bahamas); Blackman E, Ragin C (Fox Chase Cancer Center - Temple University Health System, USA); Taofe E (North Shore Long Island Jewish/Hofstra School of Medicine, Manhasset, USA); Eckstein S (University of Pittsburgh, Graduate School of Public Health and the University of Pittsburgh Cancer Institute, USA).

Author Contributions

Conceived and designed the experiments: CR DD ET RB. Performed the experiments: SE. Analyzed the data: EB KD. Contributed reagents/materials/analysis tools: CR KD DD ET. Wrote the paper: EB DD KD ET. Biospecimen and data collection: PG DD AG-B.

References

1. Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92: 1500–1510.
2. Masad LS, Aldieh I, Benning I, Minkoff H, Greenblatt RM, et al. (2001) Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women’s interagency HIV study. J Acquir Immune Defic Syndr 27: 432–442.
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM (2011) Human papillomavirus type distribution in 30,048 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128: 927–935.
4. WHO/ICO Information Centre on HPV and Cervical Cancer (2007) HPV and cervical cancer in the 2007 report. Vaccine 25, Supplement 3: C1-C26.
5. Clifford GM, Gonzalez MA, Franceschi S (2006) Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20: 2337–2344.
6. Dames DN, Ragan C, Griffith-Bowe A, Gomez P, Butler R (2009) The prevalence of cervical cytology abnormalities and human papillomavirus in women infected with the human immunodeficiency virus. Infect Agent Cancer 4 Suppl 1: S8.
7. Adler DH (2010) The impact of HAART on HPV-related cervical disease. Curr HIV Res 8: 493–497.
8. Ragan CC, Wheeler VW, Wilson JB, Bunker CH, Gollin SM, et al. (2007) Distinct distribution of HPV types among cancer-free Afro-Caribbean women from Tobago. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals 12: 510–522.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 510–527.
10. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl 3: S1–10.
11. Shrestha S, Sudenga SL, Smith JS, Bachmann LH, Wilson CM, et al. (2010) The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. Bmc Infectious Diseases 10: 295.
12. Laque AE, Jabeen M, Messing S, Lane CA, Demeter LM, et al. (2006) Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-Infected women in Rochester, New York. Journal of Infectious Diseases 194: 420–431.
13. Banura C, Franceschi S, van Doorn LJ, Arslan A, Walbwire-Mangen F, et al. (2008) Infection with human papillomavirus and HIV among young women in Kampala, Uganda. Journal of Infectious Diseases 197: 555–562.
14. Sahasrabudhe VV, Mwanahamuntu MH, Vermand SH, Hii WK, Lyon MD, et al. (2007) Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. British Journal of Cancer 96: 1480–1483.
15. Patel SJ, Mugo NR, Cohen GR, Ting J, Nguti R, et al. (2013) Multiple human papillomavirus infections and HPV `co-infectivity` as risk factors for abnormal...
cervical cytology among female sex workers in Nairobi. Int J STD AIDS 24:221–5.
16. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R (1998) A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 178: 982–986.
17. Moscicki AB, Ellenberg JH, Farhat S, Xu J (2004) Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 190: 37–45.
18. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, et al. (2001) Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184: 682–690.
19. Massad LS, Xie X, Minkoff H, Darragh TM, D’Souza G, et al. (2013) Abnormal Pap Tests and Human Papillomavirus Infections Among HIV-Infected and Uninfected Women Who Have Sex With Women. J Low Genit Tract Dis. in press PMID: 23959300.
20. Pista A, Oliveira A, Verdasca N, Ribeiro F (2011) Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect 17: 941–946.
21. Maranga IO, Hampson L, Oliver AW, He X, Gichangi P, et al. (2013) HIV Infection Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women. Open Virol J 7: 19–27.
22. De Vuyst H, Chung MH, Baussano I, Mugo NR, Tenet V, et al. (2013) Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya. International journal of cancer Journal international du cancer 133: 1441–1446.